EE417 Development and Application of a New Cost-Utility Model to Assess the Cost-Effectiveness of Palivizumab for the Prevention of Severe Respiratory Syncytial Virus (RSV) Infection in Moderate-to-Late Preterm Infants

Autor:	X. Carbonell-Estrany, J Fullarton, I Keary, B Rodgers-Gray, JE Tarride, B Paes
Rok vydání:	2022
Předmět:	Health Policy Public Health Environmental and Occupational Health
Zdroj:	Value in Health. 25:S137-S138
ISSN:	1098-3015
DOI:	10.1016/j.jval.2022.09.663
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::bcb7aff7a85cefe3cb28ceab2401ea08 https://doi.org/10.1016/j.jval.2022.09.663 Zobrazit plný text záznamu Full Text from ScienceDirect